Reuters logo
in 25 days
BRIEF-Aduro Biotech announces first patient dosed in phase 2 clinical trial of crs-207 in combination with keytruda
June 28, 2017 / 8:24 PM / in 25 days

BRIEF-Aduro Biotech announces first patient dosed in phase 2 clinical trial of crs-207 in combination with keytruda

1 Min Read

June 28 (Reuters) - Aduro Biotech Inc

* Aduro Biotech announces first patient dosed in phase 2 clinical trial of crs-207 in combination with keytruda® (pembrolizumab) for the treatment of patients with previously treated malignant pleural mesothelioma Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below